CG Oncology, Inc. (CGON) stock
CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$84.78+10.38 (+13.95%)
Close on Nov 16, 2026Market cap $7.51BP/E –Yield –
CG Oncology profit margin
Profit margin (net margin) is net income as a percentage of revenue.
CG Oncology's profit margin for the twelve months ending Sep 30, 2026 was -3851.1%. For fiscal 2025 it was -3985.0%, against -7729.5% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -3985.0% | +3744.5 |
| FY2024 | Dec 31, 2024 | -7729.5% | +16097.5 |
| FY2023 | Dec 31, 2023 | -23827.0% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -3546.8% | −917.3 |
| Q2 FY2026 | Jun 30, 2026 | -6832.8% | +59421.0 |
| Q1 FY2026 | Mar 31, 2026 | -5558.8% | +1414.4 |
| Q4 FY2025 | Dec 31, 2025 | -1779.0% | +45674.5 |
| Q3 FY2025 | Sep 30, 2025 | -2629.5% | +14399.3 |
| Q1 FY2025 | Mar 31, 2025 | -66253.8% | −63052.7 |
| Q4 FY2024 | Dec 31, 2024 | -6973.2% | +1648526.8 |
| Q3 FY2024 | Sep 30, 2024 | -47453.5% | +83302.1 |
| Q2 FY2024 | Jun 30, 2024 | -17028.8% | −12559.2 |
| Q1 FY2024 | Mar 31, 2024 | -3201.1% | – |
| Q4 FY2023 | Dec 31, 2023 | -1655500.0% | – |
| Q3 FY2023 | Sep 30, 2023 | -130755.6% | – |
| Q1 FY2023 | Mar 31, 2023 | -4469.6% | – |
See a number that looks wrong?